NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia
about
Development of thalamocortical connections between the mediodorsal thalamus and the prefrontal cortex and its implication in cognitionThe NMDA receptor complex: a multifunctional machine at the glutamatergic synapseHistamine H3 receptors and its antagonism as a novel mechanism for antipsychotic effect: a current preclinical & clinical perspectiveCannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the EvidenceANKS1B Gene Product AIDA-1 Controls Hippocampal Synaptic Transmission by Regulating GluN2B Subunit LocalizationPerspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?Perinatal Exposure to Neuregulin-1 Results in Disinhibition of Adult Midbrain Dopaminergic Neurons: Implication in Schizophrenia ModelingEffects of the nicotinic α7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in ratsA naturally occurring null variant of the NMDA type glutamate receptor NR3B subunit is a risk factor of schizophrenia.Early-life lead exposure recapitulates the selective loss of parvalbumin-positive GABAergic interneurons and subcortical dopamine system hyperactivity present in schizophrenia.GluN2C/GluN2D subunit-selective NMDA receptor potentiator CIQ reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice.Mapping the pathophysiology of schizophrenia: interactions between multiple cellular pathwaysGABA transporter-1 deficiency confers schizophrenia-like behavioral phenotypes.Targeted deletion of the C-terminus of the mouse adenomatous polyposis coli tumor suppressor results in neurologic phenotypes related to schizophrenia.LY395756, an mGluR2 agonist and mGluR3 antagonist, enhances NMDA receptor expression and function in the normal adult rat prefrontal cortex, but fails to improve working memory and reverse MK801-induced working memory impairment.Neurobiological background of negative symptoms.A Neurophysiological Perspective on a Preventive Treatment against Schizophrenia Using Transcranial Electric Stimulation of the Corticothalamic PathwayAutism Spectrum Disorders and Schizophrenia Spectrum Disorders: Excitation/Inhibition Imbalance and Developmental Trajectories.Borderline personality disorder and childhood trauma: exploring the affected biological systems and mechanisms22q11 deletion syndrome: a review of the neuropsychiatric features and their neurobiological basis.A critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammation.Human iPSC neurons display activity-dependent neurotransmitter secretion: aberrant catecholamine levels in schizophrenia neurons.Ketamine and phencyclidine: the good, the bad and the unexpected.mGluR5 positive allosteric modulation and its effects on MK-801 induced set-shifting impairments in a rat operant delayed matching/non-matching-to-sample taskAnalysis of schizophrenia and hepatocellular carcinoma genetic network with corresponding modularity and pathways: novel insights to the immune systemImpaired attention and synaptic senescence of the prefrontal cortex involves redox regulation of NMDA receptors.Major histocompatibility complex I in brain development and schizophreniaNR2B subunit in the prefrontal cortex: A double-edged sword for working memory function and psychiatric disorders.Neurological dysfunctions associated with altered BACE1-dependent Neuregulin-1 signaling.Chronic administration of aripiprazole activates GSK3β-dependent signalling pathways, and up-regulates GABAA receptor expression and CREB1 activity in ratsGluN3A: an NMDA receptor subunit with exquisite properties and functions.Chronic nicotine attenuates phencyclidine-induced impulsivity in a mouse serial reaction time task.Synaptic and Neuronal Autoantibody-Associated Psychiatric Syndromes: Controversies and HypothesesReversible overexpression of bace1-cleaved neuregulin-1 N-terminal fragment induces schizophrenia-like phenotypes in miceGlutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches.Calcium signalling and psychiatric disease: bipolar disorder and schizophrenia.The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatmentThe neurobiology and treatment of first-episode schizophrenia.MMPs: a novel drug target for schizophrenia.Vitamin D: a custodian of cell signalling stability in health and disease.
P2860
Q26830368-8C3E3B89-4747-49D0-BE44-60C0208B9E1AQ26992363-3BB22771-9A70-4430-8895-47D14B4FDB20Q28073102-F836B418-4AF2-41A5-A806-E5ACB26FBA05Q28075499-8E2FA00C-86F5-4CE6-8909-B719D766FFFAQ28511930-5973D21E-F171-405E-BE71-F64FD4C27B00Q30379983-32E1053E-642E-4EA4-9F96-F3352C2048C2Q30388740-63E4559F-ED0E-4476-A5DF-3720864A9CAFQ30391389-F6C778EB-5D40-400D-8930-E4B8A7BCB403Q30416311-35CB1EAF-B98E-4B43-B238-327E192E85F8Q30416848-FF227A93-A501-409D-8034-9987F581D724Q30419647-B324ACDC-AAC1-4070-8B02-DA778C090096Q30445820-35C906EE-1F3A-4DEF-B77C-CF17A52A599CQ30451228-35349382-0189-4CFE-9423-4C4AE2B53869Q30576089-F99FB6A8-D2A4-414F-82A9-F337B7C86652Q30747587-A92E0F60-9D1A-4EC0-8CD8-9652CF3F9FB7Q30913824-002B77E3-7C00-477D-B25B-2399A833C9ACQ33607904-FB583C18-0901-41B8-924F-3828C67225DEQ33619607-281F9409-A498-4C28-9E04-F2A331F95A2BQ33805362-E0CCBFB7-E771-4DE4-B3E4-5989EB117EB2Q34393037-1F0A683E-9FF3-4977-86C9-7D1CAED72FBEQ34405264-E67CA47C-763F-4C16-BC3A-B6ADDD511DEEQ34469459-35A156EB-B19C-4B13-8E12-868316542D89Q34480719-EDE8708B-FF03-4B2C-8810-5EEF2B012C7DQ34785084-93813533-6E48-44A5-B74E-3B8FBD8636F4Q35101267-1A3A7F6A-25C7-4E44-904E-68857D05ADF1Q35142924-4AE7F5D2-A8DD-4B35-A357-68F457455EB0Q35163148-10E501EE-608E-42F9-A222-440C70A2012BQ36052695-2D6E741F-BF93-4ED5-9390-7CB57032D6A9Q36804007-19C90472-A951-41A6-9F87-390F157A471FQ37111054-AA95BE1B-AE58-4F75-B81D-FC69EBA1F75CQ37412890-89743288-BD12-4D59-ABF8-20C75A1DF89EQ37574314-88EF0742-AA73-4210-99BF-582710E27A49Q37625400-63E2C026-BFE3-4659-8CF1-C99295CF3A2EQ37686822-9FF0F012-8B05-493B-9DD0-113F251B0F4DQ38133757-A569AFB4-9975-43CE-A224-95DFBA0CD5E7Q38191819-A551BDC9-35F5-4E61-9F56-C5BCD24C9271Q38213709-2A93624C-0EE0-49B0-8A21-E485C961E312Q38232366-4D40D3F9-5B47-4E72-BB1F-2BAD0A18BCA3Q38248546-90333143-C8CC-42C3-908E-D60E69624F7FQ38502035-ED979282-CFCA-4B91-A47B-BE4C639C5CF6
P2860
NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia
@ast
NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia
@en
type
label
NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia
@ast
NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia
@en
prefLabel
NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia
@ast
NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia
@en
P2860
P356
P1476
NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia
@en
P2093
Melissa A Snyder
Wen-Jun Gao
P2860
P356
10.3389/FNCEL.2013.00031
P577
2013-03-27T00:00:00Z